Impact of Food Structure on Micronutrient Bioavailability in Human

NCT ID: NCT03413267

Last Updated: 2019-08-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-07

Study Completion Date

2018-04-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The nutritional quality of foods strongly depends on the structure / texture of foods, because of the impact on food disintegration, and then on digestion process and nutrient utilization by the human body. However, this relationship between food structure and nutrient bioavailability is still widely unknown.

MicroNut project aims at demonstrating and evaluating in humans the impact of structure / texture changes on micronutrient bioavailability. In order to do this, four complex food matrices, with constant composition but different structures / textures, and as close as possible to real foods have been designed and are evaluated in the present study. A mixture of egg and plant proteins is the basis of these lipoprotein matrices in which four micronutrients will be followed up : two lipophilic (vitamin D and lutein) and 2 hydrophilic (vitamins B9 and B12).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main objective consists in understanding how food structure / texture impacts on micronutrient bioavailability. The second objective consists in studying food disintegration at oral phase (in the mouth) and the consequences on the bioaccessibility of hydrophilic vitamins in saliva.

The clinical study is open, monocentric, controled and randomized, in a cross experimental design.

The included volunteers (n=12) will participate in the whole two protocols. The first protocol is related to the study of vitamins B9, B12, D and lutein bioavailability during 8h kinetics, after ingestion of a food matrix (custard, biscuit, flan or sponge cake). The second protocol is related to the study of hydrophilic vitamin release during mastication of two of these matrices (biscuit and sponge cake).

The study is not performed in a double blind way. However, the measure bias will be limited because of the standardized and objective characteristic of the main criteria. Moreover, biological samples will be analysed by the same partners of the project. Each subject will be his own control, so that confusion factors related to individual variability will be eliminated.

The monocentric characteristic of the study, the low number of subjects and the expertise of the involved staff will enable to limit the number of missing data.

The randomization (latin square) has been established by a bio-statistician of the project before the study started. A document describing the randomization proceeding is confidentially kept.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Food Structure Impact on Micronutrient Bioavailability

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Bioavailability protocol : each volunteer participates in 4 interventions (4 food matrices), during 4 different days (one food matrix per day). At least 3 weeks between each intervention day. An intervention consists in food matrix ingestion (t=0) and blood sampling for 8 h postprandial (10 sampling times).

Mastication protocol : each volunteer participates in 1 session during which 2 solid matrices will be studied. For each matrix, 13 samples are proposed to the volunteer; food bolus are collected just before the volunteer feels the need of swallowing.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Because the food matrices ingested by the volunteers have different aspects, no masking is really possible. However, blood samples will be analyzed by partners without knowledge of the matrix that has been ingested.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Custard

The food matrix ingested (once by each volunteer) is a custard containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein

Group Type EXPERIMENTAL

Custard

Intervention Type OTHER

Food matrix: custard (liquid emulsion)

Flan

The food matrix ingested (once by each volunteer) is a flan containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein

Group Type EXPERIMENTAL

Flan

Intervention Type OTHER

Food matrix: flan (soft gel)

Sponge cake

The food matrix ingested (once by each volunteer) is a sponge cake containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein

Group Type EXPERIMENTAL

Sponge cake

Intervention Type OTHER

Food matrix: sponge cake (porous and spongy)

Biscuit

The food matrix ingested (once by each volunteer) is biscuits containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein

Group Type EXPERIMENTAL

Biscuit

Intervention Type OTHER

Food matrix: biscuit (thick and crunchy)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Custard

Food matrix: custard (liquid emulsion)

Intervention Type OTHER

Flan

Food matrix: flan (soft gel)

Intervention Type OTHER

Sponge cake

Food matrix: sponge cake (porous and spongy)

Intervention Type OTHER

Biscuit

Food matrix: biscuit (thick and crunchy)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* no smoking since 6 months at least
* no pathology and no medical treatment
* no history of calcium lithiasis
* BMI \>=20 and \<=30 kg/m²
* normal biological status
* no dislike for the food tested
* good dental health, no pain, no treatment in progress, no orthodontics since 3 years

Exclusion Criteria

* hypercalcemia (\>2.52 mmol/L), hyperphosphoremia (\>1.58 mmol/L)
* known pathology
* allergy or intolerance to one of the food matrix components (egg, vitamins B12, B9, D, lutein, pea, gluten)
* intake of food supplements and/or UVdose for the 3 months before the study, except enriched foods
* exposure to UV during the 2 weeks before the study and all along the study
* vitamin D \< 80µg/L
Minimum Eligible Age

20 Years

Maximum Eligible Age

30 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre de Recherche en Nutrition Humaine d'Auvergne

OTHER_GOV

Sponsor Role collaborator

University Hospital, Clermont-Ferrand

OTHER

Sponsor Role collaborator

Université d'Auvergne

OTHER

Sponsor Role collaborator

Françoise Nau

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Françoise Nau

PhD, Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ruddy Richard, Prof

Role: PRINCIPAL_INVESTIGATOR

Centre de Recherche en Nutrition Humaine d'Auvergne

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre de Recherche en Nutrition HUmaine d'Auvergne

Clermont-Ferrand, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-A01996-47

Identifier Type: OTHER

Identifier Source: secondary_id

MicroNut

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.